Lymphomed Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 6 Year, 10 Months
- Last Filing with ROC 31 Mar 2021
- Revenue Growth 481.69%
- Profit Growth 104.63%
- Ebitda 89.88%
- Net Worth 10.56%
- Total Assets 14.04%
About Lymphomed Pharma
Lymphomed Pharma Private Limited (LPPL) is a Private Limited Indian Non-Government Company incorporated in India on 28 March 2018 (Six years and ten months 29 days old ). Its registered office is in Delhi, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2021. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Prabhat Singh, Lal Ratnakar, and Juhi Kumari serve as directors at the Company.
Company Details
- Location
Delhi, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U74999DL2018PTC331736
- Company No.
331736
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
28 Mar 2018
- Date of AGM
30 Nov 2021
- Date of Balance Sheet
31 Mar 2021
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Who are the key members and board of directors at Lymphomed Pharma?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Juhi Kumari  | Director | 02-Nov-2018 | Current |
| Prabhat Singh | Director | 28-Mar-2018 | Current |
| Lal Ratnakar | Director | 28-Mar-2018 | Current |
Financial Performance of Lymphomed Pharma.
Lymphomed Pharma Private Limited, for the financial year ended 2020, experienced significant growth in revenue, with a 481.69% increase. The company also saw a substantial improvement in profitability, with a 104.63% increase in profit. The company's net worth Soared by an impressive increase of 10.56%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Lymphomed Pharma?
In 2019, Lymphomed Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Lymphomed Pharma?
Unlock and access historical data on people associated with Lymphomed Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Lymphomed Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Lymphomed Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.